BNP Paribas Financial Markets
ABUS icon

BNP Paribas Financial Markets’s Arbutus Biopharma ABUS Stock Holding History

BNP Paribas Financial Markets’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Sell
29,099
-12,462
-30% -$54.7K ﹤0.01% 4377
2026
Q1 		$187K Sell
41,561
-21,210
-34% -$92.7K ﹤0.01% 4079
2025
Q4 		$302K Sell
62,771
-27,128
-30% -$122K ﹤0.01% 3854
2025
Q3 		$408K Buy
89,899
+33,948
+61% +$125K ﹤0.01% 3663
2025
Q2 		$173K Sell
55,951
-127,297
-69% -$423K ﹤0.01% 3826
2025
Q1 		$640K Sell
183,248
-64,748
-26% -$216K ﹤0.01% 3037
2024
Q4 		$811K Sell
247,996
-58,371
-19% -$215K ﹤0.01% 2961
2024
Q3 		$1.18M Sell
306,367
-41,868
-12% -$161K ﹤0.01% 2397
2024
Q2 		$1.08M Sell
348,235
-1,200
-0.3% -$3.6K ﹤0.01% 2238
2024
Q1 		$902K Buy
349,435
+57,390
+20% +$149K ﹤0.01% 2558
2023
Q4 		$730K Buy
292,045
+49,745
+21% +$97.4K ﹤0.01% 2584
2023
Q3 		$492K Buy
242,300
+71,526
+42% +$150K ﹤0.01% 2736
2023
Q2 		$393K Buy
170,774
+85,170
+99% +$222K ﹤0.01% 2707
2023
Q1 		$259K Buy
85,604
+65,539
+327% +$185K ﹤0.01% 3047
2022
Q4 		$46.8K Sell
20,065
-18,603
-48% -$44.5K ﹤0.01% 3434
2022
Q3 		$73.9K Buy
38,668
+14,832
+62% +$34.9K ﹤0.01% 3880
2022
Q2 		$64.6K Buy
23,836
+16,093
+208% +$41.2K ﹤0.01% 3487
2022
Q1 		$23.1K Sell
7,743
-17,113
-69% -$52.4K ﹤0.01% 3705
2021
Q4 		$96.7K Buy
24,856
+9,101
+58% +$35.4K ﹤0.01% 3606
2021
Q3 		$67.6K Buy
15,755
+9,318
+145% +$31.1K ﹤0.01% 3429
2021
Q2 		$19.5K Buy
+6,437
New +$19.9K ﹤0.01% 3542
2020
Q3 		– Sell
-6
Closed -$11 – 4208
2020
Q2 		$11 Sell
6
-64
-91% -$105 ﹤0.01% 4273
2020
Q1 		$71 Hold
70
– – ﹤0.01% 4228
2019
Q4 		$195 Sell
70
-3,892
-98% -$6.3K ﹤0.01% 4311
2019
Q3 		$6.04K Hold
3,962
– – ﹤0.01% 4244
2019
Q2 		$8.24K Sell
3,962
-3,385
-46% -$8.66K ﹤0.01% 4144
2019
Q1 		$26.3K Buy
+7,347
New +$28.2K ﹤0.01% 3822
2018
Q4 		– Sell
-1,155
Closed -$10.9K – 4325
2018
Q3 		$10.9K Hold
1,155
– – ﹤0.01% 3685
2018
Q2 		$8.43K Buy
+1,155
New +$6.88K ﹤0.01% 3859

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.19B AUM 63.92% 1-Year Est. Return

BNP Paribas Financial Markets's ABUS Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Arbutus Biopharma (ABUS) stake by 30% in Q2 2026, selling an estimated $54.7K and leaving 29,099 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #4377.

BNP Paribas Financial Markets first reported a position in ABUS in Q2 2018 and has held it in 29 quarters since. The position peaked at $1.18M in Q3 2024. 163 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • BNP Paribas Financial Markets held 29,099 shares of Arbutus Biopharma worth $140K as of Q2 2026.
  • BNP Paribas Financial Markets sold 12,462 Arbutus Biopharma shares in Q2 2026, an estimated $54.7K.
  • Arbutus Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4377 holding.
  • BNP Paribas Financial Markets first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Arbutus Biopharma position peaked at $1.18M in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.